Download PDF
Thromb Haemost 1981; 46(04): 684-686
DOI: 10.1055/s-0038-1653452
Original Article
Schattauer GmbH Stuttgart

Factor IX Alloantibodies Shorten the Bovine Thromboplastin Coagulation Time of Normal Human Plasma

Karen Helene Ørstavik
The Institute of Medical Genetics, University of Oslo, Blindern, Oslo, Norway
› Author Affiliations
Further Information

Publication History

Received 28 June 1981

Accepted 10 September 1981

Publication Date:
05 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

We have previously demonstrated that neutralization of factor IX in normal plasma by heterologous antisera shortens the one stage prothrombin time determined with bovine thromboplastin. In this study, a similar effect of homologous antibodies was demonstrated. Addition of plasma from two patients with hemophilia B- and an acquired inhibitor to factor IX gave a shortening of the prothrombin time of plasma from normal persons, compared to the prothrombin time determined after addition of control plasma from a patient with hemophilia B- and no inhibitor. Addition of inhibitor plasma had a similar effect on the prothrombin time of plasma from four patients with hemophilia B+ and one patient with hemophilia Br, but had no effect on the prothrombin time of plasma from ten patients with hemophilia B-. Complexes between factor IX and the human inhibitor could be demonstrated both before and after the coagulation with bovine thromboplastin. These complexes were demonstrated as a factor IX antigen with a reduced electrophoretic mobility in crossed immunoelectrophoresis against a rabbit antiserum to factor IX. The results demonstrate that normal factor IX loses the ability to act as an inhibitor in the coagulation with bovine thromboplastin after having formed a soluble complex with a homologous antibody, although the factor IX molecules still have antigenic determinants which are free to react with the rabbit antibodies.

Keywords

Factor IX - Bovine thromboplastin - Alloantibodies
 

  • References

  • 1 Hougie C, Twomey JJ. Haemophilia BM: A new type of factor-IX deficiency. Lancet 1967; 1: 698-700
    PubMedGoogle Scholar
  • 2 Østerud B, Lavine K, Kasper CK, Rapaport SI. Isolation and properties of the abnormal factor IX molecule of hemophilia BM . Thromb Haemostas (Abst.) 1977; 38: 51
    PubMedGoogle Scholar
  • 3 Ørstavik KH, Laake K. Antiserum against factor IX shortens the bovine thromboplastin coagulation time of human plasma. Thromb Res 1978; 12: 455-465
    CrossrefPubMedGoogle Scholar
  • 4 Lechner K. Factor IX inhibitors. Thrombos Diathes Haemorrh 1971; 25: 447-459
    PubMedGoogle Scholar
  • 5 Pike JM, Yount WJ, Puritz EM, Roberts HR. Immunochemical characterization of a monoclonal γG4, λ human antibody to factor IX. Blood 1972; 40: 1-10
    PubMedGoogle Scholar
  • 6 Reisner HM, Roberts HR, Krumholz S, Yount WJ. Immunochemical characterization of a polyclonal human antibody to factor IX. Blood 1977; 50: 11-19
    PubMedGoogle Scholar
  • 7 Ørstavik KH, Nilsson IM. A study of acquired inhibitors of factor IX by means of precipitating rabbit antisera against factor IX. Thromb Res 1978; 12: 863-874
    CrossrefPubMedGoogle Scholar
  • 8 Ørstavik KH. Alloantibodies to factor IX in haemophilia B characterized by crossed immunoelectrophoresis and enzyme-conjugated antisera to human immunoglobulins. Br J Haematol 1981; 48: 15-23
    PubMedGoogle Scholar
  • 9 Nilsson IM, Hedner U, Bjørlin G. Suppression of factor IX antibody in hemophilia B by factor IX and cyclophosphamide. Ann Intern Med 1973; 78: 91-95
    CrossrefPubMedGoogle Scholar
  • 10 Ørstavik KH, Østerud B, Prydz H, Berg K. Electroimmunoassay of factor IX in hemophilia B. Thromb Res 1975; 7: 375-382
    PubMedGoogle Scholar
  • 11 Ørstavik KH. Electroimmunoassay of factor IX antigen: Increased sensitivity by enzyme amplification of immunoprecipitates. Thromb Res 1979; 15: 721-726
    CrossrefPubMedGoogle Scholar
  • 12 Quick AJ, Hussey CV. Comparison of the thrombotest with the one stage prothrombin time. N Engl J Med 1961; 265: 1286-1289
    CrossrefPubMedGoogle Scholar
  • 13 Denson KW, Biggs R, Mannucci RM. An investigation of three patients with Christmas disease due to an abnormal type of factor IX. J Clin Pathol 1968; 21: 160-165
    CrossrefPubMedGoogle Scholar
  • 14 Di Scipio RG, Kurachi K, Davie EW. Activation of human factor IX (Christmas factor). J Clin Invest 1978; 61: 1528-1538
    CrossrefPubMedGoogle Scholar
  • 15 Owren PA. The interrelationship between Normotest and Thrombotest. Farmakoterapi 1969; 25: 1-13
    PubMedGoogle Scholar
  • 16 Ørstavik KH, Laake K. Factor IX in warfarin treated patients. Thromb Res 1978; 13: 207-218
    CrossrefPubMedGoogle Scholar
  • 17 Briet E, Loeliger EA, Van Tilburg NH, Veltkamp JJ. Molecular variant of factor VII. Thromb Haemostas 1976; 35: 289-294
    PubMedGoogle Scholar
  • 18 Seligsohn U, Østerud B, Brown SF, Griffin JH, Rapaport S. Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII. J Clin Invest 1979; 64: 1056-1065
    CrossrefPubMedGoogle Scholar
  • 19 Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci 1977; 74: 5260-5264
    CrossrefPubMedGoogle Scholar